Kornimate/medical-research-clean huggingface dataset:
trimethylamine n-oxide in myocardial infarction

Conditions: Myocardial Infarction

Summary: trimethylamine-n-oxide (tmao) is produced from the metabolism of gut microbiota and is reportedly pro-atherogenic and associated with cardiovascular events. the purpose of this study is to investigate the sequential change in tmao levels by current optimal secondary prevention therapies in patients with st-elevation acute myocardial infarction (stemi) and the clinical impact of tmao levels on the progression of atherosclerosis and subsequent cardiovascular events.

this study includes patients with their first stemi. the investigators measure plasma tmao levels using the frozen plasma at the onset of stemi and 10 months later (the chronic phase). to assess plaque progression, residual syntax (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score and chronic-phase syntax score are measured. after the chronic-phase assessment of tmao and syntax score, patients are followed for cardiovascular events including death, myocardial infarction, ischemic stroke, and unstable angina pectoris with coronary revascularization.

Eligibility criteria:
inclusion criteria: * patients who admitted to the yokohama city university medical center with the diagnosis of their first stemi and who underwent primary percutaneous coronary intervention within 12 hours after onset and received follow-up coronary angiogram 10 months after the index intervention. exclusion criteria: * none
screening and access to health care for vascular disease

Conditions: Aortic Aneurysm, Abdominal; Carotid Stenosis; Peripheral Arterial Disease

Summary: this is a pilot study designed to validate our methods of recruitment, screening and data collection in the community. the project will help to establish the feasibility of the study design to lay the groundwork for a potentially larger study. the final study will allow us to estimate the incidence and prevalence of abdominal aortic aneurysm (aaa), carotid artery stenosis, and peripheral artery disease (pad) in different geographic areas in a large urban setting, as well as determine patient access to healthcare and treatment for vascular disease as related to geographic and racial differences.


Eligibility criteria:
inclusion criteria: * age 55 or older * willing/able to provide consent * willing to participate in follow-up phone calls at defined intervals for up to 5 years exclusion criteria: * unable to provide consent to participate * unwilling/unable to participate in the follow-up phone call

Keywords: aortic aneurysm, abdominal carotid stenosis peripheral arterial disease health services accessibility
clinical comparison of two silicone-hydrogel contact lenses

Conditions: Refractive Error

Summary: the objective of this study is to evaluate the clinical performance of two silicone-hydrogel contact lenses.


Eligibility criteria:
inclusion criteria: * the subject must be at least 18 and less than or equal to 39 years of age and have a need for vision correction in both eyes. * the subject must require a lens power between -1.00 to -6.00d and have no more than 1.00d of corneal cylinder. * the subject, based on his/her knowledge, must be in good general health. * the subject must be able and willing to adhere to the instructions set forth in this protocol and complete all specified evaluations. * subject must be a current adapted daily wearer of soft contact lenses with at least 6 months of cl wear. * subject must agree to wear their contact lenses in both eyes on a daily wear schedule for at least 8 hours per day every day during the study. * subject must be willing and able to use only the care systems and lubricating drops provided for the study during the 4 week period. * the subject must read, indicate understanding of and sign the informed consent form. exclusion criteria: * the subject is a rigid gas permeable (rgp) or daily disposable lens wearer. * the presence of clinically significant (grade 3 or 4) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids or associated structures. * the presence of ocular or systemic disease or need for medication which might interfere with contact lens wear or which would cause the lenses to be removed more than twice a day. (i.e., sjogren's syndrome, type ii diabetes, etc.) * slit lamp findings that would contraindicate contact lens wear such as: * pathological dry eye or associated findings * pterygium or corneal scars within the visual axis * neovascularization equal to or greater than 1mm in from the limbus * history of giant papillary conjunctivitis (gpc) worse than grade 2 * anterior uveitis or iritis (past or present) * seborrhoeic eczema * seborrhoeic conjunctivitis * a history of recurrent erosions, corneal infiltrates, corneal ulcer or fungal infections. * a known history of corneal hypoesthesia (reduced corneal sensitivity). * contact lens snellen visual acuities (va) worse than 20/30. * aphakia, keratoconus or a highly irregular cornea. * current pregnancy or lactation (to the best of the subject's knowledge) * any active participation in another clinical study at any time during this study.
effects of recurrent pe on women and offspring

Conditions: Preeclampsia; Recurrence; Hypertension

Summary: the purpose of this study is to evaluate the risk factors of recurrent preeclampsia and compare the short-term and long-term adverse outcomes of women and their offspring.

the investigators collected women delivered twice in a row in our hospital. the investigators divided these pregnant women into three groups. women in the first group did not complicate preeclampsia at both deliveries; women in the second group complicated preeclampsia at the first delivery or at the second delivery; women in the third group complicated preeclampsia at two deliveries. the investigators explore the risk factors of recurrent preeclampsia and measure blood pressure, blood lipids, thyroid function, glycosylated hemoglobin, alt, ast, et al. in one year, three years, and five years after the second delivery.

Eligibility criteria:
inclusion criteria: * women with at least twice of delivery history exclusion criteria: * women with chronic hypertension
the efficacy and safety of thymosin-α1 in patients with hbv-related aclf

Conditions: Liver Failure

Summary: a randomized controlled trial to evaluate efficacy and safety of thymosin-α1 administration in patients with hbv-related acute-on-chronic liver failure.

hepatitis b virus (hbv)-related acute-on-chronic liver failure (aclf) is a severe disease with high mortality. in this study, the investigators intend to assess the efficacy and safety of thymosin-α1 in patients with hbv-related acute-on-chronic liver failure.

Eligibility criteria:
inclusion criteria: * 1.chronic hepatitis b.(hepatitis b surface antigen positive for more than 6 months or having evidence of chronic hepatitis b virus infection). * 2.defined by an acute deterioration in transaminase greater than or equal to 5 times upper normal limit over14 days. * 3.development of jaundice (serum bilirubin greater than or equal to 10mg/dl). * 4.development of coagulopathy(pta≤40% or inr≥1.5 ). * more than one of the 5-8 criteria： * 5.development of hepatic encephalopathy. * 6.development of hepatorenal syndrome. * 7.hepatic narrowing progressively. * 8.development of massive ascites or peritonitis. * 9. willing to provide informed consent and comply with the test requirements exclusion criteria: * 1.patients who have hepatocellular carcinoma confirmed by ultrasound/ct/mr. * 2.patients who have autoimmune disease (such as inflammatory bowel disease, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, etc ) or with abnormal elevation level of autoimmune antibody. * 3.model for end-stage liver disease (meld) score \ 35. * 4.patients with significant co-morbid illnesses such as cardiovascular or respiratory or intrinsic renal diseases which by themselves may have a bearing on the outcome. * 5.patients with diseases that researchers consider inappropriate to participate in the study. * 6.patients who have disseminated intravascular coagulation. * 7.drug allergy. * 8.patients with any other contraindications to thymosin alpha1. * 9.patients who participated in other clinical trials at the same time.
barriers to care in patients with rectal bleeding in nigeria

Conditions: Colorectal Cancer

Summary: this study sought to find the health seeking behavior of patients with rectal bleeding as related to their risk to develop colorectal cancer and also assess the general practitioner's perceived barriers to colonoscopy for patients with bleeding per rectum.

patients who had rectal bleeding are invited to electronic media and print media will be invited for free medical consultation. consented patients will complete a purposely design questionnaire for the study to assess the knowledge, attitude and practice of patient with rectal bleeding as regard the possibility of occurrence of colorectal cancer. general practitioners in three cities will be contacted to assess their screening strategy for patients with rectal bleeding

Eligibility criteria:
inclusion criteria: * all adult patients with rectal bleeding that persisted for up to one month exclusion criteria: * patient that has the cause of rectal bleeding already determined before presentation

Keywords: rectal bleeding, , , attitude health seeking behaviour nigeria screening high risk patients
identification and validation model of liquid biopsy based cfdna methylation and protein biomarkers for pancreatic cancer (daybreak study)

Conditions: Cancer

Summary: daybreak is a prospective, multi-omics, observational study aimed at early detecting pancreatic cancer by combined assays for biomarkers of cfdna methylation, serum protein markers, blood mirna markers and others, in which of 450 participants will be enrolled. the development and validation of the model will be conducted in participants with early stage cancers and benign disease through a two-stage approach. the sensitivity and specificity of the model in pancreatic cancer early detection will be evaluated.


Eligibility criteria:
inclusion criteria for cancer arm participants: * able to provide a written informed consent. * able to provide sufficient and qualified blood samples for study tests. * no prior or undergoing cancer treatment (local or systematic) with either of the following: * a. pathologically confirmed cancer diagnosis within 42 days prior to the study blood draw. * b. high suspicious for cancer diagnosis by radiological or other routine clinical assessments, with confirmed cancer diagnosis through biopsy or surgical resection within 42 days after study blood draw. exclusion criteria for cancer arm participants: * insufficient qualified blood sample for study test. * during pregnancy or lactation. * recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant. * recipient of blood transfusion within 30 days prior to study blood draw. * with other known malignant tumors or multiple primary tumors. inclusion criteria for benign disease arm participants: * able to provide a written informed consent. * able to provide sufficient and qualified blood samples for study tests. * have either of the following: * a. pathological confirmed diagnosis of benign diseases within 90 days prior to the study blood draw, with no prior treatment such as surgical resection. * b. high suspicious for benign diseases diagnosis by radiological or other routine clinical assessments, with confirmed benign diseases diagnosis within 42 days after study blood draw. exclusion criteria for benign disease arm participants: * insufficient qualified blood sample for study test. * during pregnancy or lactation. * recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant. * recipient of blood transfusion within 30 days prior to study blood draw. * recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer

Keywords: pancreatic cancer liquid biopsy cell-free dna (cfdna) methylation whole blood mirna others
influence of obesity on microvascular reactivity during general anesthesia

Conditions: Obesity; Anesthesia; Microcirculation

Summary: the purpose of this study was to investigate the effect of obesity on changes in microvascular reactivity and tissue oxygen saturation (sto2) during general anesthesia using near-infrared spectroscopy in conjunction with vascular occlusion tests (vot). for this prospective observation investigation, a total of 128 patients who underwent elective surgery under general anesthesia at pusan national university hospital between june 2018 and february 2021 were participated in this study. baseline sto2 on thenar eminence, hemodynamics, and laboratory profile were monitored before (tpre) and 30 min after general anesthesia (tpost). during vascular occlusion tests (vot), the occlusion slope representing oxygen consumption of muscle and recovery slope representing microvascular reactivity were also collected at tpre and tpost. for analysis, the patients were divided into two groups: overweight (body mass index \[bmi\] ≥ 25 kg/m2) and normal weight (bmi \< 25).

preoperative laboratory findings were obtained. mean blood pressure (mbp), pulse oxygen saturation (spo2), heart rate (hr), skin temperature, and vot-derived measurements, including baseline tissue oxygen saturation (sto2), occlusion slope, minimum sto2, time to minimum sto2, recovery slope, maximum sto2, and time to baseline sto2 were recorded before (tpre) and 30 min after general anesthesia (tpost).

Eligibility criteria:
inclusion criteria: * subjects who underwent elective surgery under general anesthesia. exclusion criteria: * society of anesthesiologists (asa) physical status \> ii * patients with a neuraxial block * uncontrolled hypertension * patients with major cardiovascular disease * diabetes * pregnant individuals * peripheral vascular disease * chronic venous insufficiency * smoking: pack-years \> 10 * chronic obstructive and restrictive pulmonary disease

Keywords: obesity body mass index anesthesia, general microcirculation
pain management using mobile technology in veterans with ptsd and tbi

Conditions: Chronic Pain; Posttraumatic Stress Disorders; Traumatic Brain Injury

Summary: up to half of military veterans with traumatic brain injury (tbi) also suffer from co-occurring posttraumatic stress disorder (ptsd). both are linked to higher risk of chronic pain, one of the most common health complaints among u.s. veterans who served in operation enduring freedom (afghanistan), operation iraqi freedom (iraq), and operation new dawn (oef/oif/ond). however, pain medications elevate risk of opioid abuse, and studies indicate that veterans perceive barriers to traditional mental health treatments. little research exists regarding non-pharmacological, technology-based interventions designed to reduce pain in veterans with ptsd and tbi. mobile technology used to implement neurofeedback (eeg biofeedback) shows promise in providing a portable, low-cost intervention for reducing pain in veterans with co-occurring disorders. we aim to test the feasibility and effectiveness of using mobile neurofeedback devices for reducing pain symptoms in veterans with ptsd and tbi. veterans with ptsd, tbi, and chronic pain will receive a neurosky headset (which reads eeg brain waves) and an ipod touch with an app called mobile neurofeedback (which provides neurofeedback to induce relaxation). veterans are taught how to use these together to do neurofeedback themselves at home for 12 weeks. guided by existing research and preliminary data, we hypothesize that participants will show high levels of adherence to the neurosky + mobile neurofeedback intervention for the 3-month study duration and that participants will show statistically significant reduction in pain symptoms at 3 months compared to baseline. given links between pain and other outcomes in veterans, we will also explore effects on drug abuse, violence, and suicidality. when the research is complete, the field will be changed because we will know whether new technology reading eeg brainwaves can be used to treat symptoms among individuals suffering from chronic pain. we will also know whether neurofeedback shows promise as an effective intervention for veterans with ptsd and tbi to reduce pain and related outcomes. if this program of research is successful, its impact will be to shift approaches to managing pain in clinical practice, for both veterans and civilians


Eligibility criteria:
inclusion criteria: * military veteran who served during operation enduring freedom (oef), operation iraqi freedom (oif), and/or operation new dawn (ond) * posttraumatic stress disorder (ptsd) * traumatic brain injury (tbi) * chronic pain exclusion criteria: * history of epilepsy, seizure disorder, or have ever had a seizure or epileptic fit * pregnancy or breastfeeding

Keywords: military veterans
addiction treatment outcome monitoring study

Conditions: Alcohol Use Disorder; Substance Use Disorders

Summary: this research evaluates a tool designed for measurement-based care in addiction treatment. patients in addiction treatment will be invited to complete weekly measures indicating treatment progress and goals. for half the patients, their addiction treatment clinician will be able to view their weekly progress and goals via a secure dashboard. the research will test the feasibility and acceptability of the measurement-based care tool and will evaluate its impact on within-session discussion topics and clinical outcome measures.


Eligibility criteria:
inclusion criteria: 1. at least 18 years old. 2. self-reports that they are a patient at harborview mental health and addiction services (hmhas) clinic. 3. self-reports that they are receiving services at hmhas clinic for an alcohol or drug-related concern. 4. has a smartphone with a working phone number and a mobile plan that allows text messages and internet connection. 5. audit-c score indicates past-year hazardous drinking (summed score is at least 3 or 4 for women or men, respectively), or self-reports any drug use for non-medical reasons in the past year. 6. does not anticipate moving away from the seattle area within 6 months. 7. does not anticipate becoming incarcerated in next 6 months. 8. able to speak and read english (based on self-report). 9. must be receiving clinical services from an hmhas clinician who is also participating in the study, which will be evidenced by having at least 3 appointments with a participating hmhas clinician that were either completed within the past three months or are scheduled to occur within the next three months, verified by the electronic health record. exclusion criteria: * none
extracorporeal shockwave myocardial revascularization (esmr) therapy for the treatment of chronic heart failure

Conditions: Congestive Heart Failure

Summary: evaluation of non-invasive treatment modality, using low-intensity extracorporeal shockwaves for treatment of subjects diagnosed with congestive heart failure, with ischemic etiology.


Eligibility criteria:
inclusion criteria: 1. patient is male or female 18 years or older. 2. patient is diagnosed with a heart failure with ischemic etiology. diagnosis is based on medical history, complete physical evaluation, and echocardiography. 3. patient has documented myocardial segments with impaired contractility. diagnosis is based on rest echo. 4. patient is diagnosed with no more than 50% of segments akinetic or dyskinetic diagnosis is based on echocardiography. 5. patient is classified as nyha ii to iv. 6. patient should be on a stable dosage of medication for at least 6 weeks prior to enrollment. 7. patients ejection fraction \< 50%. 8. patient is stable and without clinical events for \> 3 months. 9. patient has signed an informed consent form. 10. patient's condition should be stable and should have a life expectancy of \>12 months. 11. patient's current and past medical condition and status will be assessed using previous medical history, physical evaluation, and the physicians (principle investigator's)medical opinion. exclusion criteria: 1. patient with intraventricular thrombus. 2. severe copd (patients with an fev1 less than .8 liters). 3. patient has chronic lung disease including emphysema and pulmonary fibrosis. 4. patient has active endocarditis, myocarditis or pericarditis. 5. patient is simultaneously participating in another device or drug study, or has participated in any clinical trial involving an experimental device or drug, including other drugs or devices enhancing cardiac neovascularization or any eswt machine for neovascularization of a competitor company within 3 months of entry into the study. 6. patients who are unwilling or unable to cooperate with study procedure. 7. patients who are unwilling to quit smoking during the study procedure (including screening phase). 8. patients who are diagnosed with severe valvular disease (regurgitation or stenosis). 9. patient is pregnant. 10. patient with a malignancy in the area of treatment without complete remission within 5 years(lungs, thorax, ribs).

Keywords: extracorporeal shockwave therapy heart failure congestive heart failure non-invasive device trial nyha (new york heart association) ischemic cardiomyopathy ischemia myocardial contractility
safety and effects of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy

Conditions: Glaucoma, Open-Angle

Summary: a multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. patients will be followed for up to 1 year.


Eligibility criteria:
inclusion criteria: * primary open-angle glaucoma in one eye * visual acuity 20/80 or better * intraocular pressure in the study eye ≤ 24 mm hg * glaucomatous visual field loss - 7 db to - 25 db exclusion criteria: * known allergy to brimonidine tartrate * uncontrolled systemic disease or infection of the eye * recent eye surgery or injections in the eye * female patients who are pregnant, nursing or planning a pregnancy
efficacy of the nanodropper device on intraocular pressure in patients with glaucoma

Conditions: Glaucoma; Ocular Hypertension; Open Angle Glaucoma

Summary: glaucoma is the leading cause of irreversible blindness worldwide. previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. the proposed study hopes to demonstrate the non-inferiority of using nanodropper to lower intraoccular pressure (iop) in glaucoma patients compared to standard of care eye drops.

the proposed study strives to demonstrate the non-inferiority of using nanodropper to lower iop in glaucoma patients compared to standard of care (soc) eye drops in a randomized trial. primary aim: demonstrate non-inferiority of using nanodropper to lower iop compared to standard of care eye drops in glaucoma patients. stable glaucoma participants and ocular hypertension participants of ages 18+ will be randomized to either use nanodropper for eye drop administration in both eyes or administer drops regularly (standard of care) in both eyes. participants will be followed-up at 1 month and 3 months.

Eligibility criteria:
inclusion criteria: 1. 18 years old or older 2. diagnosis of open-angle glaucoma (oag) or ocular hypertension (oht) 3. use of prostaglandin analogue (pga) eye drop 4. stable disease status (no visual field loss progression or increase in iop-lowering medications in the last 6 months) exclusion criteria: 1. uncontrolled glaucoma 2. have had eye surgery (including laser procedures) within the past six months 3. have a diagnosis of acute angle-closure glaucoma and/or other retinal diseases 4. use of non-pga class of iop-lowering medication